235 related articles for article (PubMed ID: 14722250)
1. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents.
Kwok JC; Richardson DR
Mol Pharmacol; 2004 Jan; 65(1):181-95. PubMed ID: 14722250
[TBL] [Abstract][Full Text] [Related]
2. Molecular pharmacology of the interaction of anthracyclines with iron.
Xu X; Persson HL; Richardson DR
Mol Pharmacol; 2005 Aug; 68(2):261-71. PubMed ID: 15883202
[TBL] [Abstract][Full Text] [Related]
3. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway.
Kwok JC; Richardson DR
Mol Pharmacol; 2003 Apr; 63(4):849-61. PubMed ID: 12644586
[TBL] [Abstract][Full Text] [Related]
4. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
5. Ferritin oxidation in vitro: implication of iron release and degradation by the 20S proteasome.
Rudeck M; Volk T; Sitte N; Grune T
IUBMB Life; 2000 May; 49(5):451-6. PubMed ID: 10902578
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit.
Zhang Y; Mikhael M; Xu D; Li Y; Soe-Lin S; Ning B; Li W; Nie G; Zhao Y; Ponka P
Antioxid Redox Signal; 2010 Oct; 13(7):999-1009. PubMed ID: 20406137
[TBL] [Abstract][Full Text] [Related]
7. Differential degradation of ferritin H- and L-chains: accumulation of L-chain-rich ferritin in lens epithelial cells.
Goralska M; Nagar S; Fleisher LN; McGahan MC
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3521-9. PubMed ID: 16186329
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms by which ascorbic acid increases ferritin levels in cultured lens epithelial cells.
Goralska M; Harned J; Grimes AM; Fleisher LN; McGahan MC
Exp Eye Res; 1997 Mar; 64(3):413-21. PubMed ID: 9196393
[TBL] [Abstract][Full Text] [Related]
9. Pathways of intracellular trafficking and release of ferritin by the liver in vivo: the effect of chloroquine and cytochalasin D.
Ramm GA; Powell LW; Halliday JW
Hepatology; 1994 Feb; 19(2):504-13. PubMed ID: 8294107
[TBL] [Abstract][Full Text] [Related]
10. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
11. Oxidation-induced ferritin turnover in microglial cells: role of proteasome.
Mehlhase J; Sandig G; Pantopoulos K; Grune T
Free Radic Biol Med; 2005 Jan; 38(2):276-85. PubMed ID: 15607911
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner.
Watts RN; Richardson DR
Eur J Biochem; 2002 Jul; 269(14):3383-92. PubMed ID: 12135476
[TBL] [Abstract][Full Text] [Related]
13. Heart protection by ischemic preconditioning: a novel pathway initiated by iron and mediated by ferritin.
Chevion M; Leibowitz S; Aye NN; Novogrodsky O; Singer A; Avizemer O; Bulvik B; Konijn AM; Berenshtein E
J Mol Cell Cardiol; 2008 Dec; 45(6):839-45. PubMed ID: 18817783
[TBL] [Abstract][Full Text] [Related]
14. A role for lysosomes in the turnover of human iron regulatory protein 2.
Dycke C; Charbonnier P; Pantopoulos K; Moulis JM
Int J Biochem Cell Biol; 2008; 40(12):2826-32. PubMed ID: 18582596
[TBL] [Abstract][Full Text] [Related]
15. Studies of iron overload. Rat liver siderosome ferritin.
Richter GW
Lab Invest; 1984 Jan; 50(1):26-35. PubMed ID: 6694350
[TBL] [Abstract][Full Text] [Related]
16. Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells.
Gardner RC; Assinder SJ; Christie G; Mason GG; Markwell R; Wadsworth H; McLaughlin M; King R; Chabot-Fletcher MC; Breton JJ; Allsop D; Rivett AJ
Biochem J; 2000 Mar; 346 Pt 2(Pt 2):447-54. PubMed ID: 10677365
[TBL] [Abstract][Full Text] [Related]
17. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome.
De Domenico I; Vaughn MB; Li L; Bagley D; Musci G; Ward DM; Kaplan J
EMBO J; 2006 Nov; 25(22):5396-404. PubMed ID: 17082767
[TBL] [Abstract][Full Text] [Related]
18. Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteasome.
Kiyomiya K; Satoh J; Horie H; Kurebe M; Nakagawa H; Matsuo S
Int J Oncol; 2002 Nov; 21(5):1081-5. PubMed ID: 12370758
[TBL] [Abstract][Full Text] [Related]
19. Uptake of ferritin by isolated rat hepatocytes. Effect of metabolic inhibitors and iron.
Adams PC; Chau LA
Clin Invest Med; 1993 Feb; 16(1):15-21. PubMed ID: 8467577
[TBL] [Abstract][Full Text] [Related]
20. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R
Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
